These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20122115)

  • 21. Synthetic Biology in the FDA Realm: Toward Productive Oversight Assessment.
    Fatehi L; Hall RF
    Food Drug Law J; 2015; 70(2):339-69, iii-iv. PubMed ID: 26302603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary: Oversight of engineered nanomaterials in the workplace.
    Maynard AD
    J Law Med Ethics; 2009; 37(4):651-8. PubMed ID: 20122107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. State biotechnology oversight: the juncture of technology, law, and public policy.
    Vito CC
    Maine Law Rev; 1993; 45(2):329-83. PubMed ID: 11652701
    [No Abstract]   [Full Text] [Related]  

  • 25. Nanotechnology risk perceptions and communication: emerging technologies, emerging challenges.
    Pidgeon N; Harthorn B; Satterfield T
    Risk Anal; 2011 Nov; 31(11):1694-700. PubMed ID: 22084861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using expert elicitation to prioritize resource allocation for risk identification for nanosilver.
    Fauss E; Gorman ME; Swami N
    J Law Med Ethics; 2009; 37(4):770-80. PubMed ID: 20122116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory 'desirables' for new health technologies.
    Farrell AM; Devaney S; Hervey TK; Murphy T
    Med Law Rev; 2013; 21(1):1-10. PubMed ID: 23420772
    [No Abstract]   [Full Text] [Related]  

  • 28. The uses of modern technologies: problems and perspectives for industrialized and developing countries.
    Banta D
    Bull Pan Am Health Organ; 1984; 18(2):139-50. PubMed ID: 6487871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From cradle-to-grave at the nanoscale: gaps in U.S. regulatory oversight along the nanomaterial life cycle.
    Beaudrie CE; Kandlikar M; Satterfield T
    Environ Sci Technol; 2013 Jun; 47(11):5524-34. PubMed ID: 23668487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upstream oversight assessment for agrifood nanotechnology: a case studies approach.
    Kuzma J; Romanchek J; Kokotovich A
    Risk Anal; 2008 Aug; 28(4):1081-98. PubMed ID: 18627547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Talk radio as the soundtrack of our lives: Participatory HIV/AIDS communication, public self-expression and Positive Talk.
    Burger M
    SAHARA J; 2015; 12():66-75. PubMed ID: 26700267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanotechnology, risk, and oversight: learning lessons from related emerging technologies.
    Kuzma J; Priest S
    Risk Anal; 2010 Nov; 30(11):1688-98. PubMed ID: 20723152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Demand for command: responding to technological risks and scientific uncertainties.
    Stokes E
    Med Law Rev; 2013; 21(1):11-38. PubMed ID: 23329016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Too small for concern? Public health and nanotechnology.
    Bowman DM; Fitzharris M
    Aust N Z J Public Health; 2007 Aug; 31(4):382-4. PubMed ID: 17725022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Redesigning the architecture of policy-making: Engaging with Māori on nanotechnology in New Zealand.
    Munshi D; Kurian PA; Morrison T; Morrison SL
    Public Underst Sci; 2016 Apr; 25(3):287-302. PubMed ID: 25193966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues.
    Mackler BF; Barach M
    J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Numeracy and the perception and communication of risk.
    Peters E
    Ann N Y Acad Sci; 2008 Apr; 1128():1-7. PubMed ID: 18469208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lay participation in medical policy making. II. Human experimentation committees: professional or representative?
    Veatch RM
    Hastings Cent Rep; 1975 Oct; 5(5):31-40. PubMed ID: 1184371
    [No Abstract]   [Full Text] [Related]  

  • 39. Federal Policy toward health care technology: the case of the National Center.
    Blumenthal D
    Milbank Mem Fund Q Health Soc; 1983; 61(4):584-613. PubMed ID: 6557372
    [No Abstract]   [Full Text] [Related]  

  • 40. What is the public's role in 'space' policymaking? Images of the public by practitioners of 'space' communication in the United Kingdom.
    Entradas M
    Public Underst Sci; 2016 Jul; 25(5):603-11. PubMed ID: 25926503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.